Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAY 3389934 in sepsis-associated coagulopathy
NL-OMON60996Phase 1Not yet recruiting
- Sponsor
- Bayer
- Start
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1 trial of BAY3389934 in sepsis and coagulopathy, sponsored by Bayer. Planned start Mar 2025; status: not yet recruiting.
02
Drugs
BAY3389934
03
Conditions
sepsiscoagulopathy
Beyond the preview
Go deeper on NL-OMON60996.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60996.